EvolveImmune Therapeutics
PrivateLast Round
Strategic
Oct 31, 2024
Total Funding Raised
$92.4M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
EvolveImmune Therapeutics is a biotechnology company developing first-in-class, multi-specific T cell engagers to address unmet needs in oncology and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
EvolveImmune Therapeutics Comparables
Compare EvolveImmune Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Synthekine | 82% | |
| ITabMed Ltd. | 81% | |
| Crossbow Therapeutics | 80% | |
EvolveImmune Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Oct 31, 2024 | ||||
| Series A Extension | Dec 13, 2023 | ||||
| Series A | Jan 1, 2020 |
Key People
Founding team and executive leadership
EvolveImmune Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Yonjin Capital | Series A |
| Elm Street Ventures | Series A Extension, Series A |
| Solasta Ventures | Series A Extension, Series A |
| Pfizer Ventures | Series A Extension, Series A |
| Takeda Ventures | Series A Extension, Series A |
| Pfizer | Series A Extension |
| Pfizer Ventures | Series A Extension, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 14, 2026
Presenting new data for EVOLVE T Cell engager platform at 2026 AACR Annual Meeting.
- Apr 14, 2026
Presenting new data at the 2026 AACR Annual Meeting.
EvolveImmune Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about EvolveImmune Therapeutics's valuation, stock price, and market status.